tmem45b Antibody

What is TMEM45B and what are its primary biological functions?

TMEM45B is a transmembrane protein with multiple biological functions across different tissues and cellular processes. Based on current research, TMEM45B:

• Plays an essential role in inflammation- and tissue injury-induced mechanical pain hypersensitivity

• Functions in innate immunity by inhibiting alphavirus replication through interaction with viral proteins Nsp1 and Nsp4

• Is predominantly expressed in IB4+ primary afferent neurons in the somatosensory system

• May act as an oncogene in osteosarcoma development and progression through the Wnt/β-catenin signaling pathway

TMEM45B is primarily localized in the trans-Golgi network, endosomes, and lysosomes, but shows limited expression at the plasma membrane or endoplasmic reticulum .

What types of TMEM45B antibodies are currently available for research?

Several validated rabbit polyclonal antibodies against TMEM45B are available for research applications:

These antibodies have been validated in applications including immunohistochemistry on paraffin-embedded tissues (IHC-P), immunocytochemistry/immunofluorescence (ICC/IF), and Western blotting (WB) .

How should TMEM45B antibodies be stored and handled to maintain reactivity?

For optimal maintenance of TMEM45B antibody reactivity:

• Store at 4°C for short-term preservation

• For long-term storage, aliquot and maintain at -20°C

• Avoid repeated freeze-thaw cycles as they may lead to denaturation and reduced activity

• Most commercial TMEM45B antibodies are supplied in PBS, pH 7.2, with 40% glycerol as a stabilizer

Proper aliquoting upon receipt is essential to minimize freeze-thaw cycles and maintain antibody performance across experiments.

What are the optimal immunostaining protocols for TMEM45B detection in cellular compartments?

Based on published research methodologies for visualizing TMEM45B in cellular compartments:

Immunofluorescence Protocol:

• Fix cells with 4% paraformaldehyde for 1 hour

• Wash cells three times with PBS

• Permeabilize with 0.2% Triton X-100

• Block with appropriate blocking buffer (5% BSA or normal serum)

• Incubate with primary TMEM45B antibody (recommended concentration: 0.25-2 μg/ml for NBP3-17632; 1-4 μg/ml for ab121488)

• Wash with PBS (3-5 times)

• Incubate with fluorophore-conjugated secondary antibody

• Wash with PBS (3-5 times)

• Counterstain with DAPI for nuclear visualization

• Mount and analyze using confocal microscopy

For co-localization studies, combine TMEM45B antibodies with organelle markers such as TGN38 (trans-Golgi marker), Rab5 (early endosome marker), Rab7 (late endosome marker), and Lamp1 (late endosome/lysosome marker) .

How can researchers validate TMEM45B antibody specificity in their experimental systems?

Comprehensive validation of TMEM45B antibody specificity should include:

• Genetic controls:

  • Compare staining between wild-type and TMEM45B knockout cells/tissues

  • Use TMEM45B siRNA knockdown to confirm reduction in signal intensity

• Expression controls:

  • Test in cells with known endogenous expression levels (e.g., osteosarcoma cell lines show higher expression than normal osteoblasts)

  • Perform overexpression experiments with tagged TMEM45B constructs

• Technical controls:

  • Include no-primary antibody control to assess non-specific binding of secondary antibody

  • Pre-adsorption with immunizing peptide should abolish specific signal

  • Cross-validate with multiple antibodies targeting different epitopes

• Signal validation:

  • Confirm expected subcellular localization (primarily in trans-Golgi network, endosomes, and lysosomes)

  • Verify molecular weight in Western blot applications

What are effective methods for fractionating cells to isolate TMEM45B-containing compartments?

Cell fractionation to isolate TMEM45B-containing compartments can be performed using:

Discontinuous Iodixanol Gradient Centrifugation Protocol:

• Lyse cells in an appropriate buffer (preserving membrane integrity)

• Subject cell lysate to discontinuous iodixanol gradient centrifugation

• Collect different fractions corresponding to cellular compartments

• Analyze fractions by Western blot, probing for:

  • TMEM45B

  • Lamp1 (endosome/lysosome marker)

  • Calnexin (ER marker)

  • TGN38 (trans-Golgi marker)

This approach has been validated in research showing that the distribution pattern of endogenous TMEM45B overlaps with endosome/lysosome marker Lamp1 but not with the ER marker calnexin .

How can TMEM45B antibodies be used to investigate its role in pain hypersensitivity mechanisms?

Research into TMEM45B's role in pain hypersensitivity can employ several antibody-based approaches:

• Immunohistochemical characterization:

  • Use TMEM45B antibodies to map expression in dorsal root ganglia (DRG) neurons

  • Co-stain with IB4 to confirm predominant expression in IB4+ primary afferent neurons

  • Compare expression patterns in control versus inflammatory pain models

• Functional analysis:

  • Perform immunoprecipitation to identify TMEM45B interaction partners in sensory neurons

  • Use phospho-specific antibodies to determine if TMEM45B undergoes post-translational modifications during inflammation

  • Develop phospho-specific TMEM45B antibodies if phosphorylation sites are identified

• Therapeutic target validation:

  • Use TMEM45B antibodies to screen potential binding partners or modulators

  • Develop function-blocking antibodies against extracellular domains

  • Perform immunohistochemistry to verify target engagement in animal models following therapeutic interventions

What experimental approaches can determine how TMEM45B inhibits viral replication?

To investigate TMEM45B's antiviral mechanism using antibody-based techniques:

• Co-immunoprecipitation studies:

  • Use TMEM45B antibodies to pull down protein complexes

  • Probe for viral proteins (Nsp1 and Nsp4) to confirm interaction

  • Map interaction domains using domain-specific antibodies

• Confocal microscopy for localization during infection:

  • Track TMEM45B redistribution during viral infection using immunofluorescence

  • Co-stain for viral replication complexes and TMEM45B

  • Quantify co-localization at different time points post-infection

• RNase protection assays:

  • Use TMEM45B antibodies to immunoprecipitate TMEM45B-RNA complexes

  • Assess protection of viral RNA from RNase treatment

  • Compare RNA stability in control versus TMEM45B-expressing cells

Research has demonstrated that TMEM45B interacts with Nsp1 and Nsp4 of Sindbis virus, interfering with their interaction and inhibiting viral replication by promoting viral RNA degradation .

How can researchers analyze TMEM45B's role in cancer using available antibodies?

For investigating TMEM45B in cancer biology:

• Expression profiling:

  • Perform immunohistochemistry on tissue microarrays to quantify TMEM45B levels across tumor types and stages

  • Compare with normal tissue counterparts

  • Correlate expression with clinical outcomes

• Signaling pathway analysis:

  • Use TMEM45B antibodies in combination with antibodies against Wnt/β-catenin pathway components

  • Perform co-immunoprecipitation to identify novel interaction partners in cancer cells

  • Evaluate changes in signaling cascade after TMEM45B knockdown/overexpression

• In vivo tumor models:

  • Monitor TMEM45B expression in xenograft models using immunohistochemistry

  • Correlate with tumor growth parameters and metastatic potential

  • Assess effects of TMEM45B-targeting interventions on tumor progression

In osteosarcoma, knockdown of TMEM45B has been shown to significantly suppress proliferation, migration, and invasion of U2OS cells through downregulation of β-catenin, cyclin D1, and c-Myc expression .

How can researchers address poor signal-to-noise ratio when using TMEM45B antibodies?

When encountering poor signal-to-noise ratio with TMEM45B antibodies:

• Optimization strategies:

  • Titrate antibody concentration (recommended range: 0.25-4 μg/ml depending on application and antibody)

  • Extend primary antibody incubation time at 4°C (overnight)

  • Test different blocking agents (5% BSA, normal serum, commercial blockers)

  • Optimize fixation methods (PFA concentration and duration)

  • Increase washing steps and durations

• Signal amplification methods:

  • Employ tyramide signal amplification (TSA) for low abundance detection

  • Use high-sensitivity detection systems (polymeric HRP or fluorophore-conjugated systems)

  • Consider biotin-streptavidin amplification systems for IHC applications

• Tissue-specific protocols:

  • For duodenum glandular cells, which show positive staining, optimize antibody dilution to 1/90 for paraffin-embedded tissues

  • For cell lines such as U-251MG, adapt protocols to account for nuclear but not nucleolar localization

What are the best approaches for simultaneous detection of TMEM45B with other cellular markers?

For multiplexed detection of TMEM45B with other markers:

• Multiple immunofluorescence:

  • Select primary antibodies from different host species to avoid cross-reactivity

  • Use highly cross-adsorbed secondary antibodies with minimal species cross-reactivity

  • Employ sequential staining protocols for primary antibodies from the same host species

  • Consider directly conjugated primary antibodies for multi-color imaging

• Organelle marker co-localization:

  • Use established markers: TGN38 (trans-Golgi), Rab5 (early endosomes), Rab7 (late endosomes), Lamp1 (lysosomes)

  • Employ spectral unmixing for overlapping fluorophore emissions

  • Use high-resolution imaging techniques such as structure illumination microscopy for precise co-localization analysis

• Sequential chromogenic detection:

  • For tissues where fluorescence is suboptimal, use sequential IHC with different chromogens

  • Strip and re-probe membranes for sequential Western blots

  • Use multiplex chromogenic IHC systems for co-expression analysis in FFPE tissues

How can researchers improve TMEM45B antibody thermostability for challenging experimental conditions?

To enhance TMEM45B antibody thermostability:

• Buffer optimization:

  • Add stabilizing agents such as glycerol (40%) for storage

  • Include protein stabilizers like BSA (0.1-1%)

  • Optimize pH and ionic strength based on antibody properties

• Antibody engineering approaches:

  • Apply consensus sequence-based methods shown to improve thermostability

  • Combine consensus sequence with structural residue pair covariance methods

  • Target mutations at exposed residues while preserving the binding epitope

• Storage and handling:

  • Divide into small aliquots immediately upon receipt

  • Add cryoprotectants for freeze-thaw stability

  • Consider lyophilization for long-term stability

Research on antibody thermostability has shown that combining consensus sequence and structural residue pair covariance methods can significantly reduce false positives in stability prediction and improve design of more stable molecules .

What emerging techniques might enhance TMEM45B antibody development and application?

Emerging technologies for TMEM45B antibody development include:

• Single B cell antibody sequencing:

  • Generation of monoclonal antibodies with higher specificity

  • Discovery of novel epitopes across TMEM45B's structure

  • Development of conformation-specific antibodies

• Nanobody and single-domain antibody technology:

  • Smaller antibody fragments for better penetration of cellular compartments

  • Improved access to conformational epitopes in transmembrane proteins

  • Enhanced stability for challenging experimental conditions

• Proximity labeling techniques:

  • Antibody-enzyme fusions (APEX2, BioID) for proximity-dependent labeling

  • Mapping of TMEM45B protein interaction networks in native cellular environments

  • In situ visualization of transient interactions with viral or signaling proteins

How might multi-omics approaches complement TMEM45B antibody-based research?

Integration of multi-omics data with antibody-based TMEM45B research:

• Proteomics integration:

  • Combine immunoprecipitation with mass spectrometry for deep interactome analysis

  • Validate antibody specificity through proteomics confirmation of target identity

  • Identify post-translational modifications affecting antibody recognition

• Transcriptomics coordination:

  • Correlate protein levels detected by antibodies with transcriptomic data

  • Investigate discrepancies between mRNA and protein levels

  • Guide antibody selection for tissues with confirmed TMEM45B expression

• Spatial biology approaches:

  • Combine antibody-based imaging with spatial transcriptomics

  • Map TMEM45B protein expression in context of tissue microenvironment

  • Correlate with single-cell transcriptomics data for comprehensive understanding

What are the most promising therapeutic applications of TMEM45B research requiring antibody tools?

Antibody tools will be crucial for developing TMEM45B-targeted therapies in:

• Pain management:

  • Use antibodies to screen for compounds disrupting TMEM45B function

  • Develop TMEM45B-targeting strategies for mechanical pain hypersensitivity

  • Target IB4+ sensory neurons expressing TMEM45B to address inflammatory pain while preserving physiological pain perception

• Antiviral therapies:

  • Screen for compounds enhancing TMEM45B's antiviral activity

  • Develop mimetics of TMEM45B interaction with viral proteins

  • Monitor TMEM45B expression during viral infections as biomarker

• Cancer therapeutics:

  • Target TMEM45B in osteosarcoma where it functions as a potential oncogene

  • Monitor therapy response through TMEM45B expression analysis

  • Develop antibody-drug conjugates for tumors overexpressing TMEM45B